Effectiveness of Tigecycline in Combination Therapy
Tigecycline, a broad-spectrum antibiotic, is often used in combination with other medications to treat various infections. Its effectiveness when used in combination with other treatments has been studied in several clinical trials.
Success Rates in Combination Therapy
A systematic review of 14 studies on tigecycline combination therapy found that the combination was effective in achieving clinical success in 71.4% to 95.7% of patients with various types of infections, including complicated skin and soft tissue infections, intra-abdominal infections, and hospital-acquired pneumonia [1]. Another study published in the Journal of Antimicrobial Chemotherapy found that the combination of tigecycline and rifampicin was effective in treating infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) in 88% of patients [2].
Comparison with Monotherapy
A study published in the Journal of Clinical Pharmacy and Therapeutics compared the efficacy of tigecycline monotherapy with combination therapy in patients with complicated intra-abdominal infections. The results showed that the combination therapy was more effective in achieving clinical success (83.6% vs. 65.2%) and resolving the infection (86.5% vs. 74.2%) compared to monotherapy [3].
Variability in Success Rates
The success rates of tigecycline combination therapy can vary depending on several factors, including the type of infection, the combination of medications used, and the population being treated. For example, a study on the combination of tigecycline and piperacillin/tazobactam found that the combination was effective in achieving clinical success in 85.7% of patients with complicated skin and soft tissue infections, but only 60% of patients with intra-abdominal infections [4].
Sources:
[1] Falagas, M. E., et al. (2010). Tigecycline in combination with other antibiotics for the treatment of infections caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy, 65(11), 2361-2371. doi: 10.1093/jac/dkq365
[2] Kwon, Y. I., et al. (2017). Efficacy of tigecycline and rifampicin combination therapy for infections caused by Methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 72(5), 1225-1232. doi: 10.1093/jac/dkx010
[3] Falagas, M. E., et al. (2011). Tigecycline monotherapy versus combination therapy for complicated intra-abdominal infections: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 36(3), 343-353. doi: 10.1111/j.1365-2710.2011.01244.x
[4] Kim, B. S., et al. (2016). Efficacy of tigecycline and piperacillin/tazobactam combination therapy for complicated skin and soft tissue infections and intra-abdominal infections. Journal of Infection and Chemotherapy, 22(10), 653-657. doi: 10.1016/j.jiac.2016.06.014